Interestingly, both high and intermediate surface ErbB3 expression corresponded to elevated levels of pAKT, which suggests that surface expression of ErbB3 above a certain threshold may help promoting NSCLC survival independently of the presence of a wild-type or of a mutated form of EGFR (see Table 1). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.